Workflow
J&J(JNJ)
icon
Search documents
最新!强生前高管加入微软
思宇MedTech· 2025-06-05 10:08
| 思宇年度活动回顾: 首届全球眼科大会 | 首届全球骨科大会 首届全球心血管大会 | | --- | --- | | 即将召开: | | | 2025年6月12日,首届全球医美科技大会 | | | 2025年7月17日,第二届全球医疗科技大会 | | | 2025年9月4-5日,第三届全球手术机器人大会 | | 2025年6月3日消息,前强生医疗科技(Johnson & Johnson MedTech)首席信息官拉里·琼斯(Larry Jones)已加入微软,担任全球医疗与生命科学 (HLS)行业领导者,向微软全球行业解决方案公司副总裁 Shelley Bransten 汇报。 Shelley Bransten 在LinkedIn上表示,琼斯拥有35年医疗科技和生命科学领域全球经验,曾推动了VELYS骨科手术机器人平台的数字化功能,支持强生 Ottava软组织手术机器人项目,擅长推动数字化转型、领导大规模组织项目、建立战略合作伙伴关系以及打造高绩效领导团队。 # 关于拉里·琼斯 拉里·琼斯在医疗科技和生命科学领域拥有超过35年的丰富经验。在强生医疗科技担任CIO期间,他主导了多个数字化转型项目,为强生医疗器 ...
Top 3 dividend stocks to buy for 2026
Finbold· 2025-06-04 14:04
Core Viewpoint - Holding dividend stocks is an effective long-term investment strategy, particularly during economic downturns, with companies that pay regular dividends often being profitable and well-positioned for future growth. Group 1: Coca-Cola (KO) - Coca-Cola has declared a quarterly dividend of $0.5100, maintaining the same amount as the previous period, with the next pay date on April 1, 2025 [2] - The company has raised its dividend for the 63rd consecutive year, now paying an annualized dividend of $2.04 per share, with a sustainable payout ratio of 77.42% [3] - Coca-Cola is expected to achieve 5-6% organic revenue growth, outperforming competitors like Pepsi [3] Group 2: Johnson & Johnson (JNJ) - Johnson & Johnson has also increased its dividend for 63 consecutive years, with the next estimated dividend amount being $1.3000, payable on June 10, 2025 [4][5] - The company reported a 2.4% year-over-year increase in revenue, with earnings per share (EPS) at $4.54, and currently has a dividend yield of approximately 3.37% [5] Group 3: Pfizer (PFE) - Pfizer's next estimated dividend is $0.4300, with the last declared amount remaining the same, payable on June 13, 2025 [6][7] - Despite declining vaccine revenues, Pfizer is upgrading its drug pipeline with 108 candidates, 30 of which are in Phase 3 [7] - The company boasts a dividend yield of over 7.37%, making it attractive among large-cap healthcare stocks [7]
5 Cheap Stocks to Buy in June
The Motley Fool· 2025-06-03 15:02
Core Viewpoint - The article highlights five stocks that are considered strong buying opportunities for June, amidst ongoing market uncertainty [1]. Group 1: Stock Recommendations - Johnson & Johnson (JNJ) is mentioned as one of the recommended stocks for purchase in June [1].
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
Prnewswire· 2025-06-03 14:45
Core Insights - Johnson & Johnson announced significant findings from two Phase 3 studies demonstrating that DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based regimens lead to deep and sustained minimal residual disease (MRD) negativity and improved long-term progression-free survival (PFS) in newly diagnosed multiple myeloma patients, regardless of transplant eligibility [1][2][3] Group 1: Study Findings - In the Phase 3 PERSEUS study, over half of the patients maintained MRD negativity for 24 months or longer with the DARZALEX FASPRO® regimen [1][2] - The addition of DARZALEX FASPRO® to the standard treatment regimen (bortezomib, lenalidomide, and dexamethasone) resulted in a 55.8% sustained MRD negativity rate at the 10⁻⁵ threshold compared to 22.6% with the standard regimen alone [2][4] - The Phase 3 CEPHEUS study showed a 60% overall MRD negativity rate at the 10⁻⁵ threshold in transplant-ineligible patients, indicating significant treatment benefits across different patient populations [1][3] Group 2: Long-term Outcomes - At a median follow-up of 47.5 months, the PFS rate was 95.3% at 48 months for patients receiving the DARZALEX FASPRO® regimen, highlighting its effectiveness in delaying disease progression [2] - The study results indicated that 69% of patients treated with the DARZALEX FASPRO® regimen remained progression-free at 54 months, compared to 48% with the standard regimen [4][5] - The overall survival (OS) favored the DARZALEX FASPRO® group, with a hazard ratio of 0.66, suggesting a potential survival benefit [4] Group 3: Safety and Efficacy - The safety profiles of DARZALEX FASPRO® in the PERSEUS and CEPHEUS studies were consistent with previously known safety data, indicating a manageable safety profile [5] - The studies included diverse patient populations, including those considered high-risk for cytogenetic abnormalities, reinforcing the broad applicability of DARZALEX FASPRO® in treating multiple myeloma [3][5] - The consistent results across different studies support the role of DARZALEX FASPRO® as a cornerstone of frontline therapy for multiple myeloma [5]
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
Prnewswire· 2025-06-03 14:45
Core Insights - Johnson & Johnson announced long-term follow-up data from the CARTITUDE-1 study, showing that 33% of patients with relapsed or refractory multiple myeloma treated with CARVYKTI® achieved progression-free survival of five years or more with a single infusion [1][3][4] - The CARTITUDE-4 analysis demonstrated significant overall survival and progression-free survival benefits across various patient subgroups, including those with standard and high-risk cytogenetics [1][5] Group 1: CARTITUDE-1 Study Findings - In the CARTITUDE-1 study, 32 out of 97 patients (33%) achieved progression-free survival for at least five years after receiving CARVYKTI® [1][3] - The median overall survival for patients in the study was reported at 60.7 months, indicating a durable response to the treatment [3] - Among the patients who remained progression-free, the majority had undergone a median of six prior lines of therapy, with 90.6% being triple-class refractory [3][7] Group 2: Safety Profile - The safety profile of CARVYKTI® in the CARTITUDE-1 study remained consistent with previous findings, with no new safety signals identified [4] - Two new cases of second primary malignancies were reported, but no new cases of Parkinsonism or cranial nerve palsies were observed [4] - The incidence of cytokine release syndrome (CRS) was noted in 84% of patients, with 4% experiencing Grade 3 or higher CRS [21] Group 3: CARTITUDE-4 Study Insights - The CARTITUDE-4 study, presented at the ASCO Annual Meeting, showed that CARVYKTI® improved progression-free survival and overall survival compared to standard care in various patient subgroups [5][9] - The study included patients with relapsed and lenalidomide-refractory multiple myeloma who had received one to three prior lines of therapy [9] Group 4: Future Directions - Johnson & Johnson is focusing on shifting treatment strategies from managing progression to aiming for a cure in multiple myeloma [6] - Upcoming presentations at the European Hematology Association (EHA) 2025 Congress will further discuss the findings from the CARTITUDE studies [6]
Johnson & Johnson's AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care
GlobeNewswire News Room· 2025-06-03 14:45
Core Insights - The Phase 3 AMPLITUDE study demonstrates the efficacy of the combination of niraparib and abiraterone acetate in delaying cancer progression and symptom worsening in patients with metastatic hormone-sensitive prostate cancer (mHSPC) with homologous recombination repair (HRR) genetic alterations, particularly BRCA [1][2][3] Study Results - The study involved 696 patients and met its primary endpoint of radiographic progression-free survival (rPFS), showing a nearly 50% reduction in disease progression for patients with BRCA alterations, with a hazard ratio (HR) of 0.52 [1][3] - Patients with any HRR alteration also benefited, with a 37% reduction in risk of progression (HR 0.63) [1] - The combination treatment reduced the risk of symptomatic progression by 56% in BRCA patients and 50% in all HRR-altered patients [1] Clinical Implications - Approximately 25% of mHSPC patients have HRR alterations, with BRCA mutations leading to faster disease progression and poorer outcomes [1][2] - The AMPLITUDE trial is the first to show clinical improvement with a PARP inhibitor-based combination in mHSPC, suggesting a new treatment option for these patients [1][2] Safety Profile - Grade 3/4 adverse events were more frequent in the niraparib combination group (75% vs. 59% in placebo), but treatment discontinuations due to adverse events remained low [1][3] Future Directions - The findings highlight the need for early initiation of personalized treatment strategies for patients with mHSPC and HRR alterations, particularly BRCA [1][2]
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
Prnewswire· 2025-06-03 14:45
Core Insights - Johnson & Johnson announced promising initial Phase 1 results for JNJ-79635322 (JNJ-5322), a novel trispecific antibody targeting relapsed or refractory multiple myeloma, showing an overall response rate (ORR) of 86.1% among 36 patients at the recommended phase 2 dose (RP2D) [1][2] - The study highlighted that the ORR was 100% in 27 patients who had not previously received BCMA and GPRC5D directed therapies, indicating strong efficacy in treatment-naive patients [1][2] - JNJ-5322 is designed to bind simultaneously to three targets, aiming to address tumor heterogeneity and resistance, which is a significant advancement over existing bispecific antibodies [1][3] Clinical Trial Details - The Phase 1 study involved 126 heavily pretreated patients with a median follow-up of 8.2 months, with a recommended RP2D of 100 mg administered every four weeks [2] - The trial's findings were presented at the 2025 ASCO Annual Meeting and will also be featured at the 2025 EHA Congress [1] Safety Profile - The most common adverse event reported was cytokine release syndrome (CRS), occurring in 59% of patients, with no Grade 3 or higher events noted [3][4] - Grade 3 or higher infections were reported in 28% of patients, and there were four treatment-emergent deaths, including one related to adenoviral encephalitis [3][4] Industry Context - Multiple myeloma is the second most common blood cancer globally, with over 35,000 new diagnoses expected in the U.S. in 2024, highlighting the need for effective treatment options [5] - The five-year survival rate for multiple myeloma patients is approximately 59.8%, indicating a significant unmet medical need in this area [5] Company Vision - Johnson & Johnson aims to transform oncology outcomes through next-generation immunotherapies, leveraging its portfolio of therapies to provide clinicians with effective treatment options for multiple myeloma [3][6]
Is Merck Stock About To Crash?
Forbes· 2025-06-03 12:25
Core Viewpoint - The comparison between Johnson & Johnson (J&J) and Merck highlights the trade-offs in investment decisions, particularly focusing on growth potential, stability, and the impact of market exclusivity on revenue [1][2][3]. Group 1: Company Performance - Merck's average revenue growth is nearly 10%, significantly higher than J&J's 4% [1]. - Merck's operating cash flow margins are 33%, compared to J&J's 28%, indicating more efficient conversion of revenue into free cash flow [1]. - Keytruda, Merck's leading oncology drug, generated $29 billion in sales last year, accounting for nearly half of Merck's total revenue [2]. Group 2: Market Challenges - Merck is set to lose U.S. market exclusivity for Keytruda in 2028, which poses a risk of a steep decline in revenue [2]. - Sales of Keytruda are projected to peak at around $36 billion by 2028, but a rapid decline to under $20 billion is likely once biosimilar competition enters the market [3]. - Historical data shows that similar drugs, like AbbVie's Humira and Roche's Herceptin, experienced sales drops of nearly 60% within two years post-patent expiration, indicating potential vulnerability for Merck [3]. Group 3: Investment Strategy - The importance of building a resilient investment portfolio that balances risk and reward is emphasized, with a reference to the Trefis High Quality portfolio outperforming major indices [4]. - Investment decisions should consider the relative attractiveness of stocks like J&J compared to cash accounts or S&P 500 ETFs, assessing expected returns against potential risks [5]. - Using Merck as an "anchor" asset can help evaluate the risk-reward dynamics in investment choices [5].
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
Prnewswire· 2025-06-03 12:00
Core Insights - The Phase 3 AMPLITUDE study demonstrates the efficacy of AKEEGA® (niraparib and abiraterone acetate) in delaying cancer progression and symptom worsening in patients with metastatic castration-sensitive prostate cancer (mCSPC) with BRCA alterations, showing a nearly 50% reduction in disease progression compared to standard care [1][2][3] Group 1: Study Results - The AMPLITUDE study involved 696 patients and met its primary endpoint of radiographic progression-free survival (rPFS), with patients having BRCA alterations showing a median rPFS not reached compared to 26 months for placebo [2][3] - The combination treatment reduced the risk of symptomatic progression by 56% in BRCA-altered patients and 50% in those with any homologous recombination repair (HRR) alterations [2][3] - An early trend toward improved overall survival (OS) was observed, with a 25% reduction in risk of death for BRCA patients and 21% for HRR patients [2][3] Group 2: Patient Demographics and Treatment Implications - Approximately 25% of mCSPC patients have HRR alterations, with about half being BRCA, who typically experience faster disease progression and poorer outcomes [2][3] - The study supports the combination of a PARP inhibitor with an androgen receptor pathway inhibitor as a new treatment option for HRR-altered mCSPC patients [2][3] Group 3: Company Background and Future Directions - Johnson & Johnson has nearly 20 years of experience in prostate cancer treatment, having treated over 750,000 patients globally [3] - The AMPLITUDE study positions Johnson & Johnson as the first to demonstrate clinical improvement with a PARP-based combination in mCSPC, indicating a significant advancement in treatment options for this patient population [3][4]
Johnson & Johnson: Relative Stability In A Wild 2025 Stock Market
Seeking Alpha· 2025-05-30 14:07
Core Viewpoint - Johnson & Johnson (JNJ) is perceived as an "iconic company" with a "boring stock," which can be advantageous during volatile market conditions [1]. Group 1 - The company is recognized for its stability and reliability, making it a suitable investment during chaotic market periods [1]. - The founder of Sungarden Investment Publishing emphasizes the importance of a disciplined and non-traditional approach to income investing, which aligns with the characteristics of JNJ [1]. Group 2 - The article does not provide any specific financial data or performance metrics related to Johnson & Johnson [2][3].